| Business Summary | | Hypertension
Diagnostics,
Inc.
is
engaged
in
the
design,
development,
manufacturing
and
marketing
of
a
proprietary
medical
device
that
it
believes
will
non-invasively
detect
subtle
changes
in
the
elasticity
of
large
and
small
arteries.
The
Company
plans
to
market
three
versions
of
its
Product:
the
HDI/PulseWave
CR-2000
Research
CardioVascular
Profiling
System,
the
CVProfilor
DO-2020
CardioVascular
Profiling
System,
and
the
CVProfilor
MD-3000
CardioVascular
Profiling
System.
The
CR-2000
Research
System
is
being
marketed
worldwide,
has
a
mechanical
device
CE
Mark
(CE0123)
which
allows
it
to
be
marketed
in
the
European
Union,
and
is
being
marketed
for
research
purposes
only
in
the
United
States. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Hypertension
Diagnostics
is
a
development
stage
company
engaged
in
the
design,
development,
assembly
and
marketing
of
a
proprietary
medical
device
for
the
non-invasive
detection
of
subtle
changes
in
the
elasticity
of
large
and
small
arteries.
For
the
nine
months
ended
3/31/01,
revenues
totalled
$2
million,
up
from
$294
thousand.
Net
loss
fell
53%
to
$1.1
million.
Results
reflect
sales
of
the
CR-2000
device,
partially
offset
by
higher
personnel
expenses. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
91;
after
tax
earnings
were
-1,152. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Kenneth Brimmer, 45 Chairman | -- | Greg Guettler, 46 Pres,
Director | $154K | Charles Chesney, Ph.D., 57 Exec.
VP, Sec., ChiefTechnology Officer | 152K | James Murphy, 56 Sr.
VP-Fin. and Admin. and CFO | 140K | Jay Cohn, M.D., 70 Director;
Chief Clinical Consultant | -- | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|